The use of oral ketamine for analgesia with dressing change in an infant with epidermolysis bullosa: report of a case.

Pediatr Dermatol

Division of Pediatric Pain Medicine, Symptom Management and Palliative Care, Department of Anesthesiology, College of Physicians and Surgeons, Columbia University, New York 10032, USA.

Published: June 2010

Epidermolysis bullosa (EB) describes a spectrum of disease from occasional bullae and callus formation to a debilitating life-threatening condition. In this study, we report the use of intravenous ketamine given orally to an infant with a phenotypically severe form of EB simplex, Dowling-Meara subtype, to achieve analgesia during painful dressing changes.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1525-1470.2009.01036.xDOI Listing

Publication Analysis

Top Keywords

epidermolysis bullosa
8
oral ketamine
4
ketamine analgesia
4
analgesia dressing
4
dressing change
4
change infant
4
infant epidermolysis
4
bullosa report
4
report case
4
case epidermolysis
4

Similar Publications

Development and validation of the Iranian Minimum Data Set for Epidermolysis Bullosa: A mixed method approach.

PLoS One

January 2025

Assistant Professor of Health Information Management, Department of Health Information Technology, Ferdows Faculty of Medical Sciences, Birjand University of Medical Sciences, Birjand, Iran.

Minimum Data Set (MDS) enables integration in data collection, uniform data reporting, and data exchange across clinical and research information systems. The current study was conducted to determine a comprehensive national MDS for the Epidermolysis Bullosa (EB) information management system in Iran. This cross-sectional descriptive study consists of three steps: systematic review, focus group discussion, and the Delphi technique.

View Article and Find Full Text PDF
Article Synopsis
  • Epidermolysis bullosa (EB) is a painful genetic skin condition causing blisters even from light touch, significantly impacting the quality of life of those affected.
  • The study aims to analyze the psychosocial effects of living with EB and identify coping mechanisms through semi-structured interviews with individuals across three countries.
  • Results reveal various physical, emotional, social, and functional challenges faced by people with EB, emphasizing the need for personalized emotional support and understanding of individual experiences.
View Article and Find Full Text PDF

Filsuvez (birch triterpenes) topical gel received approval in 2023 for the treatment of epidermolysis bullosa (EB) in pediatric patients (aged ≥6 months) and adults. It promotes wound healing by modulating inflammation, encouraging new tissue formation, and maintaining the skin barrier. In a randomized, double-blind, controlled, parallel-group, phase III trial (EASE, NCT03068780), 223 patients were randomly assigned to two groups: the first group received treatment with birch triterpenes topical gel (study gel, n = 109), and the second group received treatment with vehicle gel (n = 114).

View Article and Find Full Text PDF

Background: Epidermolysis bullosa (EB) comprises a group of genetically and clinically heterogeneous diseases characterized by skin fragility and blistering. EB is incurable, and treatment consists of preventing blisters in addition to painful and time consuming skin care, often performed by the parents, in addition to monitoring other symptoms in cases of severe EB.

Results: The purpose of this study was to explore parental experiences of caring for a child with EB.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!